[go: up one dir, main page]

BR9910594A - Herpes simplex virus, use of a herpessimplex virus, pharmaceutical composition and processes to study the function of a heterologous gene in a mammalian cell, to produce a herpes simplex virus and to treat a disorder or injury of a mammalian nervous system - Google Patents

Herpes simplex virus, use of a herpessimplex virus, pharmaceutical composition and processes to study the function of a heterologous gene in a mammalian cell, to produce a herpes simplex virus and to treat a disorder or injury of a mammalian nervous system

Info

Publication number
BR9910594A
BR9910594A BR9910594-2A BR9910594A BR9910594A BR 9910594 A BR9910594 A BR 9910594A BR 9910594 A BR9910594 A BR 9910594A BR 9910594 A BR9910594 A BR 9910594A
Authority
BR
Brazil
Prior art keywords
virus
herpes simplex
simplex virus
study
mammalian
Prior art date
Application number
BR9910594-2A
Other languages
Portuguese (pt)
Inventor
Robert Stuart Coffin
David Seymour Latchman
Original Assignee
Biovex Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biovex Ltd filed Critical Biovex Ltd
Publication of BR9910594A publication Critical patent/BR9910594A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"VìRUS DE HERPES SIMPLEX, USO DE UM VìRUS DEHERPES SIMPLEX, COMPOSIçãO FARMACêUTICA EPROCESSOS PARA ESTUDAR A FUNçãO DE UM GENEHETERóLOGO EM UMA CéLULA DE MAMìFERO, PARAPRODUZIR UM VìRUS DE HERPES SIMPLEX E PARA TRATARUM DISTúRBIO OU UMA LESãO DO SISTEMA NERVOSO DEUM MAMìFERO". Um virus de herpes simplex (HSV)compreendendo: (i) uma seq³ência de LAT de HSV inserida em umgene essencial do HSV; e (ii) uma deleção na região de LATendógena da cepa de HSV. O HSV da invenção pode ser usadono tratamento de distúrbios ou de lesões do sistema nervoso de ummamífero."SIMPLEX HERPES VIRUS, USE OF A SIMPLEX DEHERPES VIRUS, PHARMACEUTICAL COMPOSITION EPROCESSES TO STUDY THE FUNCTION OF A GENEHETEROLOGIST IN A MAMMALIAN CELL, PARAPRODUCING A MUSHROOM HERPERS VIRUS. A herpes simplex virus (HSV) comprising: (i) an HSV LAT sequence inserted into an essential HSV gene; and (ii) a deletion in the LATendogen region of the HSV strain. The HSV of the invention can be used in the treatment of disorders or injuries of the mammalian nervous system.

BR9910594-2A 1998-05-20 1999-05-20 Herpes simplex virus, use of a herpessimplex virus, pharmaceutical composition and processes to study the function of a heterologous gene in a mammalian cell, to produce a herpes simplex virus and to treat a disorder or injury of a mammalian nervous system BR9910594A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9810904.4A GB9810904D0 (en) 1998-05-20 1998-05-20 Mutant herpes simplex viruses and uses thereof
PCT/GB1999/001598 WO1999060145A1 (en) 1998-05-20 1999-05-20 Mutant herpes simplex viruses and uses thereof

Publications (1)

Publication Number Publication Date
BR9910594A true BR9910594A (en) 2001-10-30

Family

ID=10832440

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9910594-2A BR9910594A (en) 1998-05-20 1999-05-20 Herpes simplex virus, use of a herpessimplex virus, pharmaceutical composition and processes to study the function of a heterologous gene in a mammalian cell, to produce a herpes simplex virus and to treat a disorder or injury of a mammalian nervous system

Country Status (11)

Country Link
EP (1) EP1080215A1 (en)
JP (1) JP2002515256A (en)
KR (1) KR20010071292A (en)
CN (1) CN1192112C (en)
AU (1) AU756892B2 (en)
BR (1) BR9910594A (en)
CA (1) CA2328594A1 (en)
GB (2) GB9810904D0 (en)
IL (1) IL139745A0 (en)
MX (1) MXPA00011346A (en)
WO (1) WO1999060145A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6713067B2 (en) 1998-07-31 2004-03-30 Biovex Limited Herpes viruses for immune modulation
GB0009079D0 (en) * 2000-04-12 2000-05-31 Neurovex Ltd Herpes viruses for immune modulation
GB9930418D0 (en) * 1999-12-22 2000-02-16 Neurovex Ltd Replication incompetent herpes virus vectors
BRPI0107736B8 (en) 2000-01-21 2021-05-25 Biovex Ltd hsv1 js1 strain, pharmaceutical composition, and use of an hsv1 js1 strain
US7063851B2 (en) 2000-04-12 2006-06-20 Biovex Limited Herpes viruses for immune modulation
EP1618214A4 (en) * 2003-04-25 2008-02-13 Becton Dickinson Co Detection of herpes simplex virus types 1 and 2 by nucleic acid amplification
GB0317511D0 (en) 2003-07-25 2003-08-27 Biovex Ltd Viral vectors
KR102382295B1 (en) * 2013-07-17 2022-04-04 유니버시티 오브 피츠버그-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 Non-toxic HSV vectors for efficient gene delivery applications and complementing cells for their production
GB201505860D0 (en) 2015-04-07 2015-05-20 Agalimmune Ltd Therapeutic compositions and methods of use for treating cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849571A (en) * 1990-10-10 1998-12-15 University Of Pittsburgh Of The Commonwealth System Of Higher Education Latency active herpes virus promoters and their use
US5763217A (en) * 1993-11-10 1998-06-09 University Of British Columbia Method of using, process of preparing and composition comprising recombinant herpesvirus vectors
GB9524973D0 (en) * 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors

Also Published As

Publication number Publication date
WO1999060145A1 (en) 1999-11-25
GB2359083A (en) 2001-08-15
JP2002515256A (en) 2002-05-28
AU756892B2 (en) 2003-01-23
AU3946699A (en) 1999-12-06
CN1192112C (en) 2005-03-09
HK1036085A1 (en) 2001-12-21
IL139745A0 (en) 2002-02-10
EP1080215A1 (en) 2001-03-07
GB2359083B (en) 2003-03-12
CA2328594A1 (en) 1999-11-25
KR20010071292A (en) 2001-07-28
GB0030820D0 (en) 2001-01-31
GB9810904D0 (en) 1998-07-22
CN1310765A (en) 2001-08-29
MXPA00011346A (en) 2003-05-19

Similar Documents

Publication Publication Date Title
BRPI0107737B8 (en) herpes simplex virus 1 (hsv1), use of hsv1, and pharmaceutical composition
ES2150496T3 (en) CONDENSED CYCLLOALKYLIMIDAZOPYRIDIDS.
BR9912653A (en) Attenuated herpes virus, virus strain, dendritic cell, process to produce a cell, pharmaceutical composition, use of a virus, and process to perform gene therapy on a human or animal patient or to treat or prevent a pathogenic infection or cancer to treat animal patient
ATE138384T1 (en) OLIONUCLEOTIDE ALKYLPHOSPHONATE AND PHOSPHONOTHIOATE
BRPI0412845A (en) herpes virus, use of a virus, pharmaceutical composition, and method of treating a tumor in an individual in need thereof
BR9909199A (en) Physiologically acceptable composition for intra-cellular injection to treat inflammatory joint disorders and method for preparing an aqueous injectable composition for treating inflammatory joint disorders
BR9806747A (en) Transdermal therapeutic system.
GB2353529A (en) Mutant herpes simplex viruses and uses thereof
BR9507506A (en) Process to exterminate a cell process for cancer treatment composition and therapeutic kit
ES2120036T3 (en) RECOMBINANT VIRUSES AND THEIR USE IN GENETIC THERAPY.
BR9712366A (en) Herpes simplex hsv2 gd2 gene isolated, plasmid comprising the same, and processes to induce an immune response against hsv2 gd2 in an individual, to treat an individual who is infected with hsv, and to prevent an individual from becoming infected with hsv
IL78553A (en) Therapeutic compositions of phosphonylmethoxyalkyl adenines
BR0015506A (en) Gamma interferon conjugates, methods for their preparation, pharmaceutical compositions that comprise the molecules and their use in the treatment of diseases
IL128234A0 (en) Hsv strain lacking functional icp27 and icp34.5 genes
ID26956A (en) PREVENTION OF RAF KINASE USING SYMBETRIS AND NONSymmetry REPLACED BY UREA
BR9811121A (en) Product, pharmaceutical composition, and use of a product
BR0014408A (en) Immunologically significant herpes simplex virus antigens; and methods for identifying and using them
BR9815409A (en) Thienopyrimidines
BR9910594A (en) Herpes simplex virus, use of a herpessimplex virus, pharmaceutical composition and processes to study the function of a heterologous gene in a mammalian cell, to produce a herpes simplex virus and to treat a disorder or injury of a mammalian nervous system
IL121272A (en) Pharmaceutical compositions comprising adenosine and their use for treating or preventing leukopenia
BR0109928A (en) Use of an attenuated herpes virus, and, method for stimulating an immune response in a human or animal individual, or for treating or preventing a pathogenic infection or cancer in a human or animal individual.
BR0016419A (en) Method for increasing immunization responses with respect to herpes simplex virus vaccine
AR005750A1 (en) PHARMACEUTICAL COMPOSITION TO TREAT OR PREVENT ZOSTER INFECTIONS IN PERSONS INFECTED WITH THE VARICELA ZOSTER VIRUS AND PROCEDURE FOR PREPARING SUCH COMPOSITION
ATE346860T1 (en) MUTANTS OF STREPTOCOCCALTOXINS AND METHOD FOR USE THEREOF
BR9807332A (en) Leishmania antigens for use in the therapy and diagnosis of leishmaniasis

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8O, 9O E 10O ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFENTE AO DESPACHO 8.6 DA RPI 2012 DE 28/07/2009.